No Data
No Data
No Data
Shulan Healthcare, from Hangzhou, Zhejiang, submitted an IPO prospectus to be listed in Hong Kong, co-sponsor by CICC and CITIC
On March 27, 2024, Shulan Health Management Co., Ltd. (hereinafter referred to as “Shulan Healthcare”) from Hangzhou, Zhejiang submitted a prospectus to the Hong Kong Stock Exchange to be listed on the Hong Kong Main Board. This is another application after its submission expired on August 28, 2023.
Rekindle the money-making effect? Inventory and outlook of Hong Kong stock IPOs
Along with expectations of valuation restoration, market sentiment is expected to gradually pick up, and new share purchases may become popular again.
R&D expenses have declined, administrative expenses have risen, and Shulan's medical expenses are insolvent
Leju Finance Deng Rufei Shulan Medical Management Co., Ltd. (hereinafter referred to as “Shulan Healthcare”) submitted a listing to the Hong Kong Stock Exchange in August. The co-sponsors are CICC and CITIC Securities. Currently, Shulan Medical's business integrates three segments: health care services, hospital management services, and platform services. Under the multi-point operating model, Shulan Medical achieved total revenue of 1,618 billion yuan, 1,548 billion yuan, 1,778 billion yuan and 486 million yuan respectively from 2020 to 2022 and the end of March 2023. Among them, health care services contributed most of the total revenue, and each period accounted for more than 70% of the revenue.
Before the IPO of Shulan Medical, a large number of shareholders reduced their holdings and cashed out, and mysterious “outsiders” invested in shares at ultra-low prices
Leju Finance Deng Rufei Shulan Medical Management Co., Ltd. (hereinafter referred to as “Shulan Healthcare”) submitted a listing to the Hong Kong Stock Exchange in August. The co-sponsors are CICC and CITIC Securities. While Shulan Medical continues to introduce strategic investors, there are also many shareholders who have chosen to reduce their holdings or withdraw, yet in the process of transferring shares during the same period, prices varied.
Zheng Jie, son of Li Lanjuan, took over Shulan Medical and lost 225 million dollars in two and a half years
Leju Finance Deng Rufei Shulan Medical Management Co., Ltd. (hereinafter referred to as “Shulan Medical”) submitted to the Hong Kong Stock Exchange in August. The co-sponsors are CICC and CITIC Securities. Since Li Lanjuan stepped down as chairman of Shulan Medical in 2020 and was taken over by her son Zheng Jie, Shulan Medical has embarked on a path of continuous losses. From 2021 to the first quarter of 2023, the company has accumulated losses of 225 million yuan, and losses have continued to expand. Currently, Shulan Medical's business integrates the three major segments of health care services, hospital management services, and platform services. As of March 31, 2023, Shulan Medical has embraced
The academician and his wife treated the doctor, and Shulan Medical's valuation increased more than fourfold in two months
Leju Finance Deng Rufei Shulan Medical Management Co., Ltd. (hereinafter referred to as “Shulan Healthcare”) submitted a listing to the Hong Kong Stock Exchange in August. The co-sponsors are CICC and CITIC Securities. Behind Shulan Medical's IPO, there is a beautiful love story. In 1947, Li Lanjuan was born in Xialuqiao Village, Xialu Town, Shaoxing County, Zhejiang Province. After graduating from high school, she went home to become a “barefoot doctor.” Until 1970, Li Lanjuan, 23, was recommended to further her studies at Zhejiang Medical University. Here, she met Zheng Shusen, who was also recommended as a “barefoot doctor” to further her studies.
No Data